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carried out on a spore suspension of Streptomvices peucetius var. cacsius.
The microscopic examination of the aerial mycelium showed a morphological identity of this mutant with its parent culture3) and with the original Streptornyces peucetius culture6).
The cultural characteristies of mutant 416 F. I. can be summarized as follows: growth is generally good on organic as well as on synthetic media; on the former ones the color of the substrate mycelium ranges from straw-yellow to lemon-yellow, becoming ochre on aging.
A soluble pigment showing the same yellow tonalities is produced.
The parent cultures notoriously form a red substrate mycelium and a bright red soluble pigment. About the aerial mycelium which is more abundantly formed on synthetic media, its color is very similar to that of the parent culture, i.e. gray-blue-green, or gray-green. Concerning the physiological and biochemical properties, the mutant 416 F. I. differs from its parent culture in as much as it grows on L-arabinose and on esculin while it does not grow neither on mannitol nor on raffinose; furthermore this mutant differs from its parent culture because it produces a new anthracycline complex.
Because of all the differences cited above and owing to its characteristic yellow colored substrate mycelium and soluble pigment, strain 416 F. I. has to be considered a variety of the species S. peucetius to which the designation Streptomyces peucetius var. aureus (ATCC 31428; DMS 1367; FRI 4622) has been given.
Fermentation
Fermentation was carried out in 300-ml Erlenmeyer shaken flasks as well as in 500-liter stainless-steel fermenters containing the following medium (g/liter): glucose 60, brewer's dry yeast 30, The maximum concentration of the glycosidic components was reached between the sixth and seventh days of fermentation with a production of 50.70mcg/ml, consisting of the glycoside Y as the main component. When samples of fermentation broths or crude preparations are subjected to paper chromatography as reported in Table 1 , followed by bioautography using Bacillus subtilis ATCC 6633 as test organism, several active components are found to occur. The major components were designed glycosides W, X, Y and Z, while the two minor ones, designed glycosides A and C, were found to be identical with 11-deoxydoxorubicin and 11-deoxydaunorubicin2) respectively. The amount of individual anthracycline glycoside was determined on crude extracts by HPLC7) and/or by spectrophotometry after separation on paper chromatography. The lower m.p. value of VII previously reported (140~ 142°C)4 was affected by a small contamination with the starting material and the metal complex.
The 4-O-demethylation products (AlCl3, CH2Cl2, 40°C, 2 hours) of the known anthracyclinones2), 11-deoxyadriamycinone, 11-deoxy-l3-dihydrodaunomycinone and 11-deoxy-l3-deoxodaunomycinone Antibacterial Activity
The new anthracyclines display antibacterial activity. Their in vitro minimal inhibitory concentration (MIC) values obtained by using the standard tube dilution procedure on some microorganisms, arc reported in Table 4 .
Antitumor Activity
The cytotoxic activity of the new anthracyclines has been compared to that of daunorubicin, doxorubicin and carminomycin on HeLa cells in vitro, and the results are reported in Table 5 . As previously Compounds I ~Ill were also tested against L1210 leukemia, because of its natural relative resistance to anthracyclines and against the P388 leukemia, because of its high sensitivity to anthracyclines, and particularly to doxorubicin13). The results are reported in Table 6 . 
